Lux Biosciences withdraws European filing for uveitis drug
This article was originally published in Scrip
Executive Summary
Lux Biosciences has withdrawn its European marketing authorisation application for its immunosuppressant drug, Luveniq (voclosporin), 10 mg soft capsules.